Skip to main content

Kalowski Lee's Form 4 filing

Bicycle Therapeutics PLC (BCYC) · filed Aug 25, 2021

Accession no.
0001209191-21-053350
Filed
Aug 25, 2021
Trade date
Aug 23, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $247.7K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kalowski LeeCIK 0001618273Officer (President and CFO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 23, 2021Ordinary SharesMOption exerciseAcquired+7,500$1.60F2+$12,0007,500Direct
Aug 23, 2021Ordinary SharesSSaleDisposed−7,500$33.02F3−$247,6500Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 23, 2021Ordinary SharesMOption exerciseDisposed−7,500$0.00$059,774Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.366815 to GBP 1.00 as of August 23, 2021.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.056 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)